This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jere E. Goyan, PhD
Alteon Inc Northvale, NJ

JAMA. 1994;272(16):1253.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Apparently, Dr Ross-Degnan and his colleagues misunderstood what I had said in my Editorial. My point was that the FDA could not take into account the risks posed by substituted products before making a decision to withdraw a drug from the market, not that such risks would prevent the FDA from educating clinicians regarding optimal substitute drugs. I have no quarrel with the FDA attempting to identify the appropriate clinicians and educating them in regard to the risk of such substituted products, although this would be complex and require considerable resources. Nonetheless, we must look for various ways of educating such practitioners and I agree with the suggestions made in their letter. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?